{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:40:16Z","timestamp":1759138816472,"version":"3.44.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["BCF-IBW-XY-20220930-13"],"award-info":[{"award-number":["BCF-IBW-XY-20220930-13"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01206-2","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:09:39Z","timestamp":1756397379000},"page":"2465-2476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline"],"prefix":"10.1007","volume":"14","author":[{"given":"Yuyuan","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XueKai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"2","key":"1206_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-2727.163126","volume":"7","author":"KC Lakshmaiah","year":"2015","unstructured":"Lakshmaiah KC, Malabagi AS, Shetty R, Sinha M, Jayashree RS. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians. 2015;7(2):116\u201320. https:\/\/doi.org\/10.4103\/0974-2727.163126.","journal-title":"J Lab Physicians."},{"issue":"1","key":"1206_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s44259-025-00087-2","volume":"3","author":"SM Hickson","year":"2025","unstructured":"Hickson SM, Ledger EL, Wells TJ. Emerging antimicrobial therapies for Gram-negative infections in human clinical use. NPJ Antimicrob Resist. 2025;3(1):16.","journal-title":"NPJ Antimicrob Resist."},{"issue":"4","key":"1206_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","volume":"73","author":"MJ Satlin","year":"2016","unstructured":"Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336\u201345.","journal-title":"J Infect"},{"issue":"10","key":"1206_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","volume":"17","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791\u20138.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"1206_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cid\/ciu052","volume":"58","author":"MJ Satlin","year":"2014","unstructured":"Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274\u201383.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1206_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12879-025-10454-z","volume":"25","author":"S Deng","year":"2025","unstructured":"Deng S, Chen J, Zhou P, et al. Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China. BMC Infect Dis. 2025;25(1):110.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1206_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06719-y","volume":"21","author":"GL Xia","year":"2021","unstructured":"Xia GL, Jiang RL. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect Dis. 2021;21(1): 1034. https:\/\/doi.org\/10.1186\/s12879-021-06719-y.","journal-title":"BMC Infect Dis"},{"key":"1206_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105328","volume":"163","author":"M Sisay","year":"2021","unstructured":"Sisay M, Hagos B, Edessa D, et al. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163: 105328.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1206_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Xu Y, Jia P, et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016). Antimicrob Resist Infect Control. 2020;9(1):166.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"1206_CR10","first-page":"165","volume":"14","author":"A Almatroudi","year":"2025","unstructured":"Almatroudi A. Biofilm resilience: molecular mechanisms driving antibiotic resistance in clinical contexts. Biology (Basel). 2025;14(2):165.","journal-title":"Biology (Basel)"},{"issue":"3","key":"1206_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","volume":"40","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of eravacycline: a novel fluorocycline. Pharmacotherapy. 2020;40(3):221\u201338.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"1206_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103451","volume":"22","author":"MG Danieli","year":"2023","unstructured":"Danieli MG, Antonelli E, Auria S, et al. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev. 2023;22(11): 103451.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1206_CR13","first-page":"322","volume":"183","author":"JH North Jr","year":"1996","unstructured":"North JH Jr, Weber TK, Rodriguez-Bigas MA, et al. The management of infectious and noninfectious anorectal complications in patients with leukemia. J Am Coll Surg. 1996;183(4):322\u20138.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"1206_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00134-009-1678-y","volume":"36","author":"M Joannidis","year":"2010","unstructured":"Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. Intensive Care Med. 2010;36(3):392\u2013411.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1206_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13756-020-0706-0","volume":"9","author":"TT Yang","year":"2020","unstructured":"Yang TT, Luo XP, Yang Q, et al. Different screening frequencies of carbapenem-resistant Enterobacteriaceae in patients undergoing hematopoietic stem cell transplantation: which one is better? Antimicrob Resist Infect Control. 2020;9(1):49.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"9","key":"1206_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/cid\/ciz219","volume":"69","author":"JA Tornheim","year":"2019","unstructured":"Tornheim JA, Starks AM, Rodwell TC, et al. Building the framework for standardized clinical laboratory reporting of next-generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex. Clin Infect Dis. 2019;69(9):1631\u20133.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1206_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","volume":"22","author":"PY Huang","year":"2024","unstructured":"Huang PY, Hsu CK, Tang HJ, et al. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. Expert Rev Anti-Infect Ther. 2024;22(6):387\u201398.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"11","key":"1206_CR18","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1206_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567\u201388.","journal-title":"Drugs"},{"issue":"4","key":"1206_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/21505594.2016.1207834","volume":"8","author":"JT Thaden","year":"2017","unstructured":"Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):403\u201316.","journal-title":"Virulence"},{"key":"1206_CR21","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024:ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"2","key":"1206_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107247","volume":"64","author":"A Belati","year":"2024","unstructured":"Belati A, Diella L, Bavaro DF, et al. Intravenous fosfomycin as adjunctive therapy for gram-negative bacteria bloodstream infections: a propensity score adjusted retrospective cohort study. Int J Antimicrob Agents. 2024;64(2): 107247.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1206_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2013.04.004","volume":"76","author":"E Evren","year":"2013","unstructured":"Evren E, Azap OK, \u00c7olako\u011flu \u015e, et al. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin, and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis. 2013;76(3):335\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"1206_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12866-024-03581-1","volume":"24","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xu L, Zhang K, et al. Synergistic effect of fosfomycin and colistin against KPC-producing Klebsiella pneumoniae: pharmacokinetics-pharmacodynamics combined with transcriptomic approach. BMC Microbiol. 2024;24(1):430.","journal-title":"BMC Microbiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01206-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:10Z","timestamp":1759138030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01206-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01206-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (Yuyuan Lv; Xin Zhang; Qingya Cui; Mengyun Li; Lian Bai; Yan yu; Xuekai Li; Xiaoqian Chen; Depei Wu; Xiaowen Tang)declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This work represents original research that has not been disseminated through any prior conference presentations, preprint servers, or peer-reviewed publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies involving humans were approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. The studies were conducted in accordance with local legislation and institutional requirements. Written informed consent was obtained from the patients for the publication of this case series. And This study was performed in accordance with the ethical standards of the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}